Home › Lung Cancer › New York
Lung Cancer clinical trials in New York
93 studies for Lung Cancer are looking for participants at sites in New York.
Cities in New York
- New York City60 studies
- Queens22 studies
- Greenburgh17 studies
- Buffalo16 studies
- Rochester15 studies
- The Bronx13 studies
- Staten Island12 studies
- New Rochelle11 studies
- Syracuse6 studies
- Queensbury5 studies
- Yonkers4 studies
- Albany3 studies
- Rome3 studies
- Brooklyn3 studies
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- NYU Langone's Perlmutter Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- Optum Medical Care, PC, Westbury
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06765109Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Northwell Health Imbert Cancer Center, Bay Shore
- Maimonides Medical Center, Brooklyn
- Roswell Park Cancer Institute, Buffalo
- and 18 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT04267848Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Glens Falls Hospital, Glens Falls
- Upstate Cancer Center at Oswego, Oswego
- University of Rochester, Rochester
- and 7 more
RecruitingPhase 3
Ages 70 and older · All sexes · Updated Sep 30, 2026 · NCT06096844Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Roswell Park Cancer Institute, Buffalo
- Memorial Sloan Kettering Commack, Commack
- The Cancer Institute at Saint Francis Hospital, East Hills
- and 13 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT04181060Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Roswell Park Cancer Institute, Buffalo
- Memorial Sloan Kettering Cancer Center, New York
- Montefiore Medical Center, The Bronx
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06881784Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Montefiore Medical Center-Einstein Campus, The Bronx
- Montefiore Medical Center-Weiler Hospital, The Bronx
- Montefiore Medical Center - Moses Campus, The Bronx
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06498635A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
- GSK Investigational Site, East Syracuse
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07099898Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
- MSK Commack, Commack
- MSK Westchester, East White Plains
- Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy, Long Island City
- and 3 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07476287Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- New York Oncology Hematology, Albany
- New York Oncology Hematology, Clifton Park
- Hematology Oncology Associates of Rockland, Nyack
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07222566This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Hematology Oncology Associates of Rockland, Nyack
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06758401A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Cayuga Medical Center ( Site 0086), Ithaca
- University Hospital at Stony Brook ( Site 0054), Stony Brook
- White Plains Hospital ( Site 0091), White Plains
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06312137A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Roswell Park Cancer Institute IDS, Buffalo
- Memorial Sloan Kettering Hospital, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06172478A Registry for People With Lung Cancer
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06424327Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, Buffalo
RecruitingPhase 2
Ages 18 to 95 · All sexes · Updated Sep 23, 2026 · NCT05061550A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- WMCHealth Advanced Physician Services, Hawthorne
- Local Institution - 0128, Rochester
- Local Institution - 0518, Schenectady
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07063745Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Columbia University, New York
- NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola
- NYU Langone Health, New York
- Weill Cornell Medical College, New York
- and 1 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07100080Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- Nuvance Health, Poughkeepsie
- Suny-Stony Brook University Cancer Center, Stony Brook
- White Plains Hospital, White Plains
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06712316A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- NYU Langone Health Perlmutter Cancer Center, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT07629960Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT06287775Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07349537Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT05786924The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Columbia University Medical Center, New York
- Memorial Sloan Kettering, New York
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 15, 2026 · NCT04585750Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- NYU Langone Hospital - Long Island Investigational Pharmacy, Mineola
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06293898Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06625775A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- SUNY Upstate Medical University, Syracuse
- Montefiore Einstein Cancer Center, The Bronx
- Clinical Research Alliance, Westbury
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06793215A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Maimonides Cancer Center, Brooklyn
- Northwell Health/ RJ Zuckerberg Cancer Center, Lake Success
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06119581A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
- Columbia University Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06561685A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- NYU Langone Health - Long Island, Mineola
- New York University (NYU) Clinical Cancer Center, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT06400472AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, New York
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Sep 4, 2026 · NCT07038343Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
- Roswell Park Cancer Institute, Buffalo
- Perlmutter Cancer Center - NYU Langone Health, New York
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06343402Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Queens Hospital Center, Jamaica
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Stony Brook University Medical Center, Stony Brook
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Sep 2, 2026 · NCT05334069Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Northwell Health/R.J. Zuckerberg Cancer Center, Lake Success
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 1, 2026 · NCT07185997Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Cornell University - NewYork-Presbyterian/Weill Cornell Medical Center, New York
- White Plains Hospital, White Plains
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 1, 2026 · NCT06712355Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- New York Cancer & Blood Specialists, New York
- University of Rochester - Wilmot Cancer Institute, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT06582017Hotspot Stereotactic Ablative Radiotherapy Versus Traditional Stereotactic Ablative Radiotherapy for the Treatment of Early-Stage Non-Small Cell Lung Cancer
- Roswell Park Cancer Institute, Buffalo
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT07718672Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Cancer
- Roswell Park Cancer Institute, Buffalo
Recruiting
Ages 21 and older · All sexes · Updated Aug 19, 2026 · NCT05787834GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
- Roswell Park Cancer Institute, Buffalo
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT07017829Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- Northwell Health Imbert Cancer Center, Bay Shore
- Sands Cancer Center, Canandaigua
- Memorial Sloan Kettering Commack, Commack
- and 21 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05624996Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
- NYU Langone Hospital - Brooklyn, Brooklyn
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- and 7 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT06500481From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.